Intensification Treatment of Ovarian Cancer by PIPAC
Recruiting
Phase 2
Interventional Study
Advanced Epithelial Ovarian Cancer
Peritoneal Carcinomatosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Female
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 160 (estimated)
- Sponsor
- Moscow Regional Oncological Dispensary · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn whether repeated cisplatin-based PIPAC added to standard TC chemotherapy can improve outcomes in women aged 18-75 years with newly diagnosed FIGO IIIB-IIIC epithelial ovarian cancer and visually detectable peritoneal carcinomatosis. The main questions are whether repeated PIPAC increases the rate of complete surgical cytoreduction (CRS R0) and whether it…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female, age 18-75 years.
* Histologically verified ovarian cancer with peritoneal carcinomatosis.
* FIGO stage IIIB or IIIC.
* visually detectable peritoneal carcinomatosis.
* Peritoneal metastatic involvement documented preoperatively by ultrasound, CT, MRI, PET-CT, or equiva…
Contacts